Company news
Monopar Therapeutics Inc. (NASDAQ:MNPR) news
Every Monopar Therapeutics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AAS...
August 19, 2026
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 13, 2026
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 12, 2026
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
July 22, 2026
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Comm...
July 20, 2026
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Vers...
June 26, 2026
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wils...
June 1, 2026
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 14, 2026
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms...
April 19, 2026
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
March 27, 2026
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
March 2, 2026
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
November 13, 2025
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - T...
November 9, 2025
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
October 15, 2025
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance...
September 23, 2025
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
September 23, 2025
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological ...
September 14, 2025
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association ...
September 3, 2025
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
August 12, 2025
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
June 11, 2025
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
June 3, 2025
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
May 13, 2025
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
May 7, 2025
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
April 29, 2025
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
March 31, 2025
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded...
December 20, 2024
Monopar Therapeutics : Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR 101 Lu Form 8 K
December 6, 2024
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
December 5, 2024
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
December 3, 2024
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
November 8, 2024
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
October 30, 2024
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
October 28, 2024
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
October 28, 2024
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
October 24, 2024
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
October 22, 2024
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
October 15, 2024
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
October 7, 2024
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
September 12, 2024
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
August 27, 2024
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
August 21, 2024
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
August 14, 2024
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
August 9, 2024
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
August 9, 2024
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
July 9, 2024
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
June 25, 2024
Monopar and NorthStar Amend & Extend Collaboration
June 11, 2024
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Ann...
June 10, 2024
Monopar Announces CFO Succession
May 24, 2024
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
May 9, 2024